Blood markers may forecast heart and kidney trouble years after ICU kidney failure
NCT ID NCT07596407
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 412 patients who survived severe acute kidney injury in the ICU to see if two biomarkers (galectin-3 and CD146) can predict future heart attacks, strokes, kidney failure, or death. Researchers will track patients' health through phone interviews and medical records. The goal is to better identify who needs close follow-up after leaving the hospital.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors identify ICU survivors at highest risk for future heart or kidney complications, allowing earlier monitoring and preventive care.
What could go wrong
This is an observational study that does not test a new treatment. The biomarkers may not prove useful for predicting outcomes, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL INJURY, ACUTE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Réanimation médico-chirurgicale, Hôpital Avicenne
Bobigny, France
Contact Phone: •••-•••-•••• Email: •••••@•••••